中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2015年
13期
126-127
,共2页
美沙拉嗪%溃疡性%结肠炎%柳氮磺砒啶
美沙拉嗪%潰瘍性%結腸炎%柳氮磺砒啶
미사랍진%궤양성%결장염%류담광비정
Mesalazine%Ulcerative%Colitis%Sulfasalazine
目的:分析美沙拉嗪治疗溃疡性结肠炎的临床疗效。方法搜集本院肛肠科2014年1月~2015年1月收治的46例溃疡性结肠炎患者,根据使用药物的不同分为两组,甲组给予美沙拉嗪药物治疗,乙组给予柳氮磺砒啶药物治疗,对比两组治疗效果。结果两组比较,甲组患者治疗总有效率为96.0%(24/25),高于乙组的85.7%(18/21),且甲组不良反应的发生率8.0%,低于乙组的23.8%,差异有统计学意义(P<0.05);治疗后两组组织学积分均有所下降,且甲组组织学积分下降情况大于乙组,差异有统计学意义(P<0.05)。结论美沙拉嗪治疗溃疡性结肠炎的临床疗效显著,可提高患者的治愈率,降低不良反应的发生率。
目的:分析美沙拉嗪治療潰瘍性結腸炎的臨床療效。方法搜集本院肛腸科2014年1月~2015年1月收治的46例潰瘍性結腸炎患者,根據使用藥物的不同分為兩組,甲組給予美沙拉嗪藥物治療,乙組給予柳氮磺砒啶藥物治療,對比兩組治療效果。結果兩組比較,甲組患者治療總有效率為96.0%(24/25),高于乙組的85.7%(18/21),且甲組不良反應的髮生率8.0%,低于乙組的23.8%,差異有統計學意義(P<0.05);治療後兩組組織學積分均有所下降,且甲組組織學積分下降情況大于乙組,差異有統計學意義(P<0.05)。結論美沙拉嗪治療潰瘍性結腸炎的臨床療效顯著,可提高患者的治愈率,降低不良反應的髮生率。
목적:분석미사랍진치료궤양성결장염적림상료효。방법수집본원항장과2014년1월~2015년1월수치적46례궤양성결장염환자,근거사용약물적불동분위량조,갑조급여미사랍진약물치료,을조급여류담광비정약물치료,대비량조치료효과。결과량조비교,갑조환자치료총유효솔위96.0%(24/25),고우을조적85.7%(18/21),차갑조불량반응적발생솔8.0%,저우을조적23.8%,차이유통계학의의(P<0.05);치료후량조조직학적분균유소하강,차갑조조직학적분하강정황대우을조,차이유통계학의의(P<0.05)。결론미사랍진치료궤양성결장염적림상료효현저,가제고환자적치유솔,강저불량반응적발생솔。
Objective To analysis the clinical effect of mesalazine medication in treatment of ulcerative colitis. Methods 46 patients with ulcerative colitis were chose who were treated in anorectal department in our hospital from January 2014 to January 2015. The patients were divided into group A and group B according to different treatment methods. The group A was given mesalazine medication treatment and the group B was given sulfasalazine medication treatment. And then made a comparative study on treatment effects between two groups. Results The total effective rate of group A was 96.0%(24/25) which was much higher than that was 85.7%(18/21)of Group B. There was a great differential between two groups(P<0.05). The incidence of adverse effect of Group A was 8.0%which was much lower than that was 23.8%in Group B. There was significant difference between two groups. The histopathologic scores had been declined after treatment in two groups. The decreased degree of group A was much better than that of Group B. There was a great differential between two groups(P<0.05). Conclusion The clinical efficacy of mesalazine medication in treatment of ulcerative colitis is significantly. It is conducive to increasing cure rate and reducing the rate of adverse.